Dr. Twardowski on Steps Toward Optimal Sequencing for mCRPC Therapies

Przemyslaw W. Twardowski, MD
Published: Friday, Dec 16, 2016



Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, discusses the necessary steps to take toward determining optimal sequencing of treatments for patients with metastatic castration-resistant prostate cancer.

There is no good answer yet for this question in prostate cancer, Twardowski explains. In other tumor types, there is an advantage because there are specific biomarkers that guide therapy, as they can predict response to select agents. However, this is not confirmed yet in prostate cancer.

However, one that is showing promise is the specific variance of the androgen receptor (AR), which may predict responsiveness to various types of agents. Perhaps other subgroups or mutations in AR can also guide treatment decisions in the future, he adds.

There are also some specific genomic alterations that are being found in prostate cancer that have indications for drug development, one of which are DNA repair genes. The mutations in those genes can possibly predict the responsiveness to PARP inhibitors.
 


Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, discusses the necessary steps to take toward determining optimal sequencing of treatments for patients with metastatic castration-resistant prostate cancer.

There is no good answer yet for this question in prostate cancer, Twardowski explains. In other tumor types, there is an advantage because there are specific biomarkers that guide therapy, as they can predict response to select agents. However, this is not confirmed yet in prostate cancer.

However, one that is showing promise is the specific variance of the androgen receptor (AR), which may predict responsiveness to various types of agents. Perhaps other subgroups or mutations in AR can also guide treatment decisions in the future, he adds.

There are also some specific genomic alterations that are being found in prostate cancer that have indications for drug development, one of which are DNA repair genes. The mutations in those genes can possibly predict the responsiveness to PARP inhibitors.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x